Haisco Pharma forecasts 297%-321% net profit growth for first three quarters of 2026

The standout here is the composition of the growth: recurring profit rising nearly as fast as headline profit suggests the gain is operational, driven by innovative-drug sales, rather than a one-off accounting item. The licensing upfronts add a lumpier, less predictable revenue stream that can flatter a single period without recurring. For a pharma name, that mix matters more than the headline percentage. The open question is whether domestic innovative-drug momentum holds once licensing payments normalize — and how much of the forecast depends on those upfronts.